Effects of PTEN inhibition on regulation of tau phosphorylation in an okadaic acid-induced neurodegeneration model

International Journal of Developmental Neuroscience

Volumn 30, Issue 6, 2012, Pages 411-419

  Chen, Zhou ^a   Chen, Bin ^a   Xu, Wen Fang ^a   Liu, Rong Fang ^a   Yang, Jian ^a   Yu, Chang Xi ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Akt PKB; Alzheimer's disease; Glycogen synthase kinase 3; Okadaic acid; PTEN; Tau phosphorylation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REPRESSION; GENE; GENE SILENCING; MOLECULAR PATHOLOGY; NERVE DEGENERATION; PHOSPHATASE AND TENSIN HOMOLOGUE DELETED ON CHROMOSOME 10 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MEMBRANE PROTEINS; NEUROBLASTOMA; OKADAIC ACID; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAU PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 84865865584     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2012.08.003     Document Type: Article

References (56)

1. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., Nelson R.B., McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2910-2915.
2. Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nature Medicine 1996, 2:783-787.
3. Arias C., Sharma N., Davies P., Shafit-Zagardo B. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. Journal of Neurochemistry 1993, 61:673-682.
4. Avila J., Lucas J.J., Perez M., Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiological Reviews 2004, 84:361-384.
5. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO Journal 2004, 23:2586-2596.
6. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience 2007, 8:663-672.
7. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. Journal of Neurochemistry 2004, 89:1313-1317.
8. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
9. Boe R., Gjertsen B.T., Vintermyr O.K., Houge G., Lanotte M., Doskeland S.O. The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Experimental Cell Research 1991, 195:237-246.
10. Brunden K.R., Trojanowski J.Q., Lee V.M. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nature Reviews Drug Discovery 2009, 8:783-793.
11. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4240-4245.
12. Carracedo A., Salmena L., Pandolfi P.P. SnapShot: PTEN signaling pathways. Cell 2008, 133(550):e551.
13. Chang N., El-Hayek Y.H., Gomez E., Wan Q. Phosphatase PTEN in neuronal injury and brain disorders. Trends in Neurosciences 2007, 30:581-586.
14. Crowder R.J., Freeman R.S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. Journal of Biological Chemistry 2000, 275:34266-34271.
15. Dawson J.F., Holmes C.F. Molecular mechanisms underlying inhibition of protein phosphatases by marine toxins. Frontiers in Bioscience 1999, 4:D646-D658.
16. Devred F., Barbier P., Douillard S., Monasterio O., Andreu J.M., Peyrot V. Tau induces ring and microtubule formation from alphabeta-tubulin dimers under nonassembly conditions. Biochemistry 2004, 43:10520-10531.
17. Ducruet A.P., Vogt A., Wipf P., Lazo J.S. Dual specificity protein phosphatases: therapeutic targets for cancer and Alzheimer's disease. Annual Review of Pharmacology and Toxicology 2005, 45:725-750.
18. Georgescu M.M. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010, 1:1170-1177.
19. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. Journal of Neurochemistry 2005, 93:105-117.
20. Grundke-Iqbal I., Rolkova G., Konstekova E., Iqbal K. Biological markers in Alzheimer's disease. Bratislavske Lekarske Listy 2006, 107:359-365.
21. Hetman M., Kanning K., Cavanaugh J.E., Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. Journal of Biological Chemistry 1999, 274:22569-22580.
22. Honkanen R.E., Codispoti B.A., Tse K., Boynton A.L., Honkanan R.E. Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases. Toxicon 1994, 32:339-350.
23. Ittner L.M., Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience 2011, 12:65-72.
24. Johnson G.V., Stoothoff W.H. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science 2004, 117:5721-5729.
25. Kerr F., Rickle A., Nayeem N., Brandner S., Cowburn R.F., Lovestone S. PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Letters 2006, 580:3121-3128.
26. Kesavapany S., Patel V., Zheng Y.L., Pareek T.K., Bjelogrlic M., Albers W., Amin N., Jaffe H., Gutkind J.S., Strong M.J., Grant P., Pant H.C. Inhibition of Pin1 reduces glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. Molecular Biology of the Cell 2007, 18:3645-3655.
27. Kim D., Su J., Cotman C.W. Sequence of neurodegeneration and accumulation of phosphorylated tau in cultured neurons after okadaic acid treatment. Brain Research 1999, 839:253-262.
28. Kyrylenko S., Roschier M., Korhonen P., Salminen A. Regulation of PTEN expression in neuronal apoptosis. Brain Research: Molecular Brain Research 1999, 73:198-202.
29. Lachyankar M.B., Sultana N., Schonhoff C.M., Mitra P., Poluha W., Lambert S., Quesenberry P.J., Litofsky N.S., Recht L.D., Nabi R., Miller S.J., Ohta S., Neel B.G., Ross A.H. A role for nuclear PTEN in neuronal differentiation. Journal of Neuroscience 2000, 20:1404-1413.
30. Li D.M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Research 1997, 57:2124-2129.
31. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
32. Lim Y.W., Yoon S.Y., Choi J.E., Kim S.M., Lee H.S., Choe H., Lee S.C., Kim D.H. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochemical and Biophysical Research Communications 2010, 395:207-212.
33. Liu K., Lu Y., Lee J.K., Samara R., Willenberg R., Sears-Kraxberger I., Tedeschi A., Park K.K., Jin D., Cai B., Xu B., Connolly L., Steward O., Zheng B., He Z. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nature Neuroscience 2010, 13:1075-1081.
34. Lovestone S., Reynolds C.H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997, 78:309-324.
35. Marino S., Krimpenfort P., Leung C., van der Korput H.A., Trapman J., Camenisch I., Berns A., Brandner S. PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 2002, 129:3513-3522.
36. Martin D., Salinas M., Lopez-Valdaliso R., Serrano E., Recuero M., Cuadrado A. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. Journal of Neurochemistry 2001, 78:1000-1008.
37. Okamura H., Yoshida K., Morimoto H., Haneji T. PTEN expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells. Journal of Cellular Biochemistry 2005, 94:117-125.
38. Otaegi G., Yusta-Boyo M.J., Vergano-Vera E., Mendez-Gomez H.R., Carrera A.C., Abad J.L., Gonzalez M., de la Rosa E.J., Vicario-Abejon C., de Pablo F. Modulation of the PI 3-kinase-Akt signalling pathway by IGF-I and PTEN regulates the differentiation of neural stem/precursor cells. Journal of Cell Science 2006, 119:2739-2748.
39. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
40. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:6364-6369.
41. Rickle A., Bogdanovic N., Volkmann I., Zhou X., Pei J.J., Winblad B., Cowburn R.F. PTEN levels in Alzheimer's disease medial temporal cortex. Neurochemistry International 2006, 48:114-123.
42. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
43. Sakakibara A., Horwitz A.F. Mechanism of polarized protrusion formation on neuronal precursors migrating in the developing chicken cerebellum. Journal of Cell Science 2006, 119:3583-3592.
44. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
45. Shi G.D., OuYang Y.P., Shi J.G., Liu Y., Yuan W., Jia L.S. PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochemical and Biophysical Research Communications 2011, 404:941-945.
46. Sonoda Y., Mukai H., Matsuo K., Takahashi M., Ono Y., Maeda K., Akiyama H., Kawamata T. Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neuroscience Letters 2010, 471:20-24.
47. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 1997, 15:356-362.
48. Stein T.D., Johnson J.A. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. Journal of Neuroscience 2002, 22:7380-7388.
49. Takai A., Bialojan C., Troschka M., Ruegg J.C. Smooth muscle myosin phosphatase inhibition and force enhancement by black sponge toxin. FEBS Letters 1987, 217:81-84.
50. Wang J., Tung Y.C., Wang Y., Li X.T., Iqbal K., Grundke-Iqbal I. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Letters 2001, 507:81-87.
51. Wang J.Z., Xia Y.Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. Journal of Alzheimers Disease 2012.
52. Wei W., Wang X., Kusiak J.W. Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. Journal of Biological Chemistry 2002, 277:17649-17656.
53. Wu D.N., Pei D.S., Wang Q., Zhang G.Y. Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rat hippocampus. Neuroscience Letters 2006, 404:98-102.
54. Yoon S.Y., Choi J.E., Huh J.W., Hwang O., Nam Hong H., Kim D. Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer's disease. Neuroreport 2005, 16:223-227.
55. Zhang Z., Simpkins J.W. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Research 2010, 1359:233-246.
56. Zhang X., Li F., Bulloj A., Zhang Y.W., Tong G., Zhang Z., Liao F.F., Xu H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB Journal 2006, 20:1272-1274.